Your session is about to expire
← Back to Search
sipIT Intervention for Kidney Stones
N/A
Waitlist Available
Led By Necole M Streeper, MD
Research Sponsored by Penn State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month, 3 months, and 12 months
Awards & highlights
No Placebo-Only Group
Summary
This trial will test if using tech tools to monitor water intake can help people with a history of kidney stones better follow their doctor's recommended water consumption.
Who is the study for?
This trial is for English-speaking adults over 18 who've had a kidney stone in the last 5 years, can use a smartphone, and are willing to wear a Fitbit daily for a year. They should drink less than 2 liters of fluid per day. It's not for pregnant women or those planning pregnancy, people moving away or having surgery soon, on certain medical treatments, with specific health conditions that affect fluid intake or urine collection.
What is being tested?
The sipIT study tests if tools like wrist sensors, smart water bottles, and apps can help people with past kidney stones follow doctor's advice on drinking enough fluids. Participants will use these tech aids to see if they improve their hydration habits.
What are the potential side effects?
There may be no direct side effects from using the sipIT tools themselves; however, increasing fluid intake could potentially lead to more frequent urination. People with certain health conditions might have risks associated with higher fluid consumption.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 month, 3 months, and 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month, 3 months, and 12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
24-hr urine volume
Habit strength for fluid intake
Past-week fluid intake
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: sipITExperimental Treatment1 Intervention
Participants receive education and a digital tool to monitor their fluid intake and remind them when they have lapsed in regular fluid intake.
Group II: ControlActive Control1 Intervention
Participants receive usual care (i.e., education about fluid intake guidelines and encouragement to meet those guidelines).
Find a Location
Who is running the clinical trial?
Penn State UniversityLead Sponsor
368 Previous Clinical Trials
127,347 Total Patients Enrolled
3 Trials studying Kidney Stones
3,594 Patients Enrolled for Kidney Stones
Necole M Streeper, MDPrincipal InvestigatorMedical College of Wisconsin
David E Conroy, PhDPrincipal InvestigatorThe Pennsylvania State University
4 Previous Clinical Trials
553 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have been diagnosed with cystine kidney stones before.I am able to understand and agree to the study's procedures and risks.I have had a painful kidney stone in the last 5 years.I do not plan to have surgery or move away within the next year.I am not on any treatments that would interfere with the study.I have been using lithium for a long time.I am 18 years old or older.I cannot drink a lot of fluids or collect urine for 24 hours due to my health condition.
Research Study Groups:
This trial has the following groups:- Group 1: sipIT
- Group 2: Control
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger